Background/Objectives: Non-alcoholic fatty liver disease (NAFLD), also referred to as metabolic dysfunction-associated fatty liver disease (MAFLD), is the most common chronic liver disease, closely associated with obesity and Metabolic Syndrome (MetS). Perilipin-2 (PLIN2), the most abundant lipid droplet protein in the liver, is linked to lipid accumulation and inflammation, the hallmarks of NAFLD. The role of PLIN2 in NAFLD etiopathogenesis remains partially understood. This study aims to elucidate the relationship between serum PLIN2 levels and other disease-related parameters in NAFLD, investigate the role of PLIN2 in disease pathogenesis, and evaluate its utility as a biomarker in NAFLD diagnosis. Methods: The study included 46 patients diagnosed with NAFLD who presented internal medicine outpatient clinics and 44 healthy controls. Results: Serum PLIN2 level was found to be statistically significantly higher in the NAFLD patient group compared to the control group. In the NAFLD group, a statistically significant positive correlation was detected between PLIN2 and Body Mass Index (BMI), hip circumference, C-reactive protein (CRP), and platelet count. In ROC analysis, taking the cut-off value for serum PLIN2 level as 5.52 ng/mL predicted the diagnosis of NAFLD with 50% sensitivity and 97.7% specificity. Conclusions: PLIN2 determination demonstrated high specificity at the proposed cut-off value and may represent a promising complementary biomarker for NAFLD, particularly when interpreted alongside other clinical and laboratory parameters. Circulating PLIN2 appears to be influenced by metabolic and inflammatory parameters.
Background/Objectives: This study aimed to evaluate the serum activating transcription factor 4 (ATF4) and toll-like receptor 4 (TLR4) levels in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and to explain the mechanism in the inflammatory and fibrogenic signaling pathways that are thought to play a role in the development of MASLD through these parameters. Methods: Eighty-eight patients with MASLD and 88 age-sex matched healthy controls were included in this study. Serum ATF4 and TLR4 concentrations were measured using an ELISA method. Results: Both TLR4 (p = 0.010) and ATF4 (p < 0.001) levels were higher in the MASLD group. In this group, TLR4 showed a negative correlation with age. ROC analysis indicated that an ATF4 value of 1.305 or above identified MASLD with 93.2% sensitivity and 85.2% specificity (AUC = 0.968, p < 0.001). For TLR4, a cut-off of 343.5 yielded a sensitivity of 54.5% and a specificity of 70.5% (AUC = 0.613, p = 0.01), indicating limited discriminative ability. Conclusions: Patients with MASLD had higher serum TLR4 and ATF4 levels, consistent with their involvement in inflammatory and fibrotic pathways. ATF4 showed strong diagnostic performance and may serve as a useful non-invasive marker for early MASLD. When evaluated together with TLR4, it may provide complementary information regarding inflammatory pathway activation.